These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29500406)

  • 1. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
    Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
    Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
    Mithraprabhu S; Khong T; Spencer A
    Cell Death Dis; 2014 Mar; 5(3):e1134. PubMed ID: 24651437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
    Aouali N; Broukou A; Bosseler M; Keunen O; Schlesser V; Janji B; Palissot V; Stordeur P; Berchem G
    PLoS One; 2015; 10(6):e0130339. PubMed ID: 26091518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
    Mazzone R; Zwergel C; Mai A; Valente S
    Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
    Terui Y
    Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
    Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
    Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
    Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
    Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
    McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
    Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.
    Moreaux J; Reme T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
    Br J Cancer; 2013 Aug; 109(3):676-85. PubMed ID: 23868005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Drugs for Multiple Sclerosis.
    Peedicayil J
    Curr Neuropharmacol; 2016; 14(1):3-9. PubMed ID: 26813117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
    Gkotzamanidou M; Terpou E; Kentepozidis N; Terpos E
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
    Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC
    Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Combinations with HDAC Inhibitors in Antitumor Therapy.
    Arrighetti N; Corno C; Gatti L
    Crit Rev Oncog; 2015; 20(1-2):83-117. PubMed ID: 25746106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.